L-PRF for Gum Disease
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment L-PRF for gum disease?
Is L-PRF safe for use in humans?
How is the L-PRF treatment for gum disease different from other treatments?
What is the purpose of this trial?
The study will compare the clinical outcomes of the two procedures, open flap debridement (OFD) compared to open flap debridement with leukocyte and platelet-rich fibrin (L-PFR) as well as differences in patient postoperative pain perception.
Research Team
Charles Powell, DDS, MS
Principal Investigator
The University of Texas Health Science Center at San Antonio
Eligibility Criteria
This trial is for adults aged 18-89 with gum disease needing periodontal surgery, who smoke less than 10 cigarettes a day. It's not for pregnant women or those planning to become pregnant, heavy smokers (>10 cigarettes/day), people unable to follow the study schedule, prisoners, or mentally incompetent individuals.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo periodontal surgery with either OFD or OFD + L-PRF
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Leukocyte Platelet-rich fibrin
Leukocyte Platelet-rich fibrin is already approved in United States, European Union for the following indications:
- Periodontal regeneration
- Bone grafting
- Sinus lift procedures
- Socket preservation
- Periodontal regeneration
- Bone grafting
- Sinus lift procedures
- Socket preservation
- Guided bone and tissue regeneration
Find a Clinic Near You
Who Is Running the Clinical Trial?
The University of Texas Health Science Center at San Antonio
Lead Sponsor